News archive
Showing 706 results
February 2021
-
Story Education and Awareness
Understanding Heart Health Inequities During Black History Month
After years of decline, cardiovascular disease mortality is on the rise, with a disproportionate impact on Black Americans
-
Media Release
Novartis Entresto® granted expanded indication in chronic heart failure by FDA
-
Media Release
Novartis Entresto® granted expanded indication in chronic heart failure by FDA
Entresto is the first and only therapy approved in the US to treat patients diagnosed with guideline-defined heart failure to include both those with heart failure with reduced ejection fraction (… -
Story Global Impact
Reimagining Healthcare in Challenging Times: Novartis in Society US Report for 2020
Novartis is striving every day to help patients, strengthen communities, drive sustainability and build a more equitable healthcare system for all.
-
Story Education and Awareness
Telemedicine is helping patients in underserved communities access quality healthcare
The Novartis US Foundation partners with local groups to improve healthcare in underserved communities, including by expanding use of telemedicine.
January 2021
-
Media Release
Novartis ligelizumab (QGE031) receives FDA Breakthrough Therapy designation for patients with chronic idiopathic urticaria (CIU)
Ligelizumab is the first treatment to receive FDA Breakthrough Therapy designation in chronic idiopathic urticaria (CIU) in patients with an inadequate response to H1 anthistamines1 Currently… -
Statement
Novartis US response to COVID-19
December 2020
-
Story Hope
Working Together at Novartis to Fight COVID-19 and Help People in Need
Novartis is fighting COVID-19 broadly, from committing R&D resources to better understand and treat the disease to reaching out to individuals and communities in need.
-
Media Release
Novartis announces positive FDA Advisory Committee recommendation for use of Entresto® to treat patients with HFpEF
-
Media Release
Novartis announces positive FDA Advisory Committee recommendation for use of Entresto® to treat patients with HFpEF
The Committee voted 12 to 1 that the data presented support the use of Entresto in treatment of patients with heart failure with preserved ejection fraction (HFpEF) Potential Q1 2021 sNDA approval…